Evaluation of the Impact of the Presence of a Pharmacy Technician on the Quality and Cost of Drug Therapy (OPTI-PP)
Evaluation of the Impact of the Presence of a Pharmacy Technician on the Quality and Cost of Drug Therapy in the Hepato-Gastroenterology Department of the Nîmes University Hospital
The main objective of this study is to evaluate the impact of the presence of a pharmacy technician in a care unit (Hepato-Gastroenterology Department) on detected medication errors.
This is a before-after study consisting of three sequential phases:
Month 1: one month of observation of what is happening in the department Month 2: one month wash out period Month 3: active participation of a pharmacy technician in the department
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The secondary objectives of this study are:
A- To assess the impact of the presence of a pharmacy technician on the ratio of the number of patients with at least one medication error / number of included patients hospitalized in the service.
B- To characterize detected medication errors.
C- To identify and evaluate the potential causes of medication errors.
D- To evaluate whether the presence of a pharmacy technician reduces nursing time spent on medication management.
E- To evaluate the economic impact of the presence of a pharmacy technician.
F- To evaluate the acceptability of the intervention by the nursing staff and pharmacy technicians using questionnaires.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Nîmes Cedex 09, Frankreich, 30029
- CHRU de Nîmes - Hôpital Universitaire Carémeau
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- The patient must be insured or beneficiary of a health insurance plan
- The patient is hospitalized in the Hepato-Gastroenterology Department of the Nîmes University Hospital
Exclusion Criteria:
- The patient is under judicial protection
- The patient, or his/her legal guardian, expresses opposition to participation in the study
- It is impossible to correctly inform the patient
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: 1st observational period (before experimental intervention)
Patients in this arm are included during a first month of observation before the intervention is implemented. Intervention: One month of department-wide observation |
A pharmacy technician will be present full time in the care unit from Monday to Friday between 8:30 and 17h for 1 month for observational purposes only.
During this phase, the pharmacy technician observes the current practices of preparation and administration of medication by nurses.
He / she will collect medication errors and other observational data.
|
|
Experimental: 2nd obs. period (during experimental intervention)
Following a one-month wash-out period, patients in this arm are included during a second month of observation during which the intervention is implemented. Intervention: Pharm Tech participates in department |
Following a 1 month wash-out period, a pharmacy technician will again be present full time (in practice, two technicians will relay each other) in the care unit from Monday to Friday between 8:30 and 17h for 1 month.
He/she will actively take part in drug care activities in the department: management of product pathways, verification of injectable preparation, advice, etc. Medication errors and other observational data will be collected.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The following ratio (relative units): Number of medication errors / number of medications administered and omitted from among all those listed on the prescription for admission
Zeitfenster: 5 days
|
Primary Outcome Measure as given in protocol: Number of medication errors / number of medications administered and omitted from among all those listed on the prescription for admission (during month 1 versus during month 3).
|
5 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of patients with at least one medication error / total number of hospitalized patients included in the service
Zeitfenster: 5 days
|
5 days
|
|
|
For each medication error: the name of the drug
Zeitfenster: 5 days
|
5 days
|
|
|
For each medication error: the type of error
Zeitfenster: 5 days
|
Errors are classifies as one of the following types: Omission; Drug; Dosage form; Expired or damaged drug; Dose; Concentration; Frequency of administration; Administration technique; Route of Administration; Rate of administration; Duration of administration; Administration Time; Patient; Drug interaction. |
5 days
|
|
For each medication error: the severity index
Zeitfenster: 5 days
|
5 days
|
|
|
For each medication error: when (which step) the error occurred during the drug pathway
Zeitfenster: 5 days
|
The considered steps are: Writing the prescription Medical decision for the prescription Transcription Pharmaceutical analysis Deliverance Preparation / reconstitution Pillbox Administration Procurement Storage Compliance Therapeutic and clinical follow-up |
5 days
|
|
For each medication error: the evolution of the adverse drug event, if occurred
Zeitfenster: 5 days
|
5 days
|
|
|
For each medication error: the criticality of the error
Zeitfenster: 5 days
|
Criticality is graded according to the following classes:
3E: treatment or surgery with temporary harm 3F: longer duration of hospitalization with temporary harm 3G: permanent harm 3H: involving a life-threatening harm 3I: death Criticality is determined by the concordance of two, independent expert opinions; or, in case of discordance, the concordance of 2 out 3 expert opinions. |
5 days
|
|
The potential causes of medication errors
Zeitfenster: 5 days
|
5 days
|
|
|
The average number of interruptions per hour during preparation or administration of drug doses by nurses
Zeitfenster: 5 days
|
5 days
|
|
|
The number of patients for whom personal treatments were managed by the nursing staff on admission / number of patients who brought their personal treatments to the care unit
Zeitfenster: 5 days
|
5 days
|
|
|
The number of patients for whom personal treatments were returned by the nursing staff at hospital discharge / number of patients who brought their personal treatments to the care unit
Zeitfenster: 5 days
|
5 days
|
|
|
Nursing staff time dedicated to: the preparation of individual doses
Zeitfenster: 5 days
|
5 days
|
|
|
Nursing staff time dedicated to: ordering health products
Zeitfenster: 5 days
|
5 days
|
|
|
Nursing staff time dedicated to: stock management and exceptional orders
Zeitfenster: 5 days
|
5 days
|
|
|
Nursing staff time dedicated to: the delivery, receipt and storage of health products
Zeitfenster: 5 days
|
5 days
|
|
|
Nursing staff time dedicated to: cabinet inventories
Zeitfenster: 5 days
|
5 days
|
|
|
Nursing staff time dedicated to: the management of expired drugs
Zeitfenster: 5 days
|
5 days
|
|
|
The number of calls made to the central pharmacy
Zeitfenster: 5 days
|
5 days
|
|
|
Staff time dedicated to managing exceptional requests
Zeitfenster: 5 days
|
5 days
|
|
|
The number of drugs consumed
Zeitfenster: 5 days
|
5 days
|
|
|
The number of medical devices consumed
Zeitfenster: 5 days
|
5 days
|
|
|
The number of immobilized drugs
Zeitfenster: 5 days
|
5 days
|
|
|
The number of immobilized medical devices
Zeitfenster: 5 days
|
5 days
|
|
|
The cost of adverse drug events care
Zeitfenster: 5 days
|
5 days
|
|
|
Care staff satisfaction questionnaire
Zeitfenster: 5 days
|
5 days
|
|
|
Pharmacy technician satisfaction questionnaire
Zeitfenster: 5 days
|
5 days
|
Mitarbeiter und Ermittler
Ermittler
- Studienleiter: Géraldine Leguelinel-Blache, PharmD, PhD, Centre Hospitalier Universitaire de Nimes
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- LOCAL/2015/GL-01
- 2015-A01309-40 (Andere Kennung: RCB number)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .